MyBiotics is a microbiome pharmaceutical company developing live bacteria based products.
MyBiotics developed two innovative technologies; MyCrobeTM and SuperDonorTM that allow us to be in the front of the microbiome field. Both technologies resolve the three critical factors in the probiotic development market. Delivery, Targeting and Colonization. MyCrobeTM and SuperDonorTM provide single or multi-bacterial combinations for targeted treatment, whole microbiome restoration and the first actual screening method to replace FMT microbiome transplantations.
The bacteria delivered using MyBiotics technologies are potentially capable of shifting unbalanced bacterial communities, often associated with a diseased state, to a healthy one. The company completed the first step of the technology development and pre clinical evaluation and is now in the process of upscale and product development towards clinical studies.
